- Home
- KIRK vs SYBX Comparison
KIRK vs SYBX Comparison
Compare KIRK & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIRK
- SYBX
- Stock Information
- Founded
- KIRK 1966
- SYBX N/A
- Country
- KIRK United States
- SYBX United States
- Employees
- KIRK N/A
- SYBX N/A
- Industry
- KIRK Diversified Commercial Services
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- KIRK Miscellaneous
- SYBX Health Care
- Exchange
- KIRK Nasdaq
- SYBX Nasdaq
- Market Cap
- KIRK 20.2M
- SYBX 16.5M
- IPO Year
- KIRK 2002
- SYBX N/A
- Fundamental
- Price
- KIRK $1.46
- SYBX $1.36
- Analyst Decision
- KIRK Buy
- SYBX Hold
- Analyst Count
- KIRK 2
- SYBX 1
- Target Price
- KIRK $4.50
- SYBX N/A
- AVG Volume (30 Days)
- KIRK 203.3K
- SYBX 19.0K
- Earning Date
- KIRK 03-20-2025
- SYBX 03-18-2025
- Dividend Yield
- KIRK N/A
- SYBX N/A
- EPS Growth
- KIRK N/A
- SYBX N/A
- EPS
- KIRK N/A
- SYBX N/A
- Revenue
- KIRK $458,411,000.00
- SYBX $2,777,000.00
- Revenue This Year
- KIRK N/A
- SYBX N/A
- Revenue Next Year
- KIRK $0.37
- SYBX N/A
- P/E Ratio
- KIRK N/A
- SYBX N/A
- Revenue Growth
- KIRK N/A
- SYBX 292.23
- 52 Week Low
- KIRK $1.39
- SYBX $1.22
- 52 Week High
- KIRK $3.00
- SYBX $2.04
- Technical
- Relative Strength Index (RSI)
- KIRK 37.18
- SYBX 45.23
- Support Level
- KIRK $1.51
- SYBX $1.31
- Resistance Level
- KIRK $1.58
- SYBX $1.40
- Average True Range (ATR)
- KIRK 0.07
- SYBX 0.07
- MACD
- KIRK -0.00
- SYBX 0.00
- Stochastic Oscillator
- KIRK 0.00
- SYBX 60.61
About KIRK Kirkland's Inc. COMMONSTOCK
Kirkland's Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.